Skip to main content

Day: November 16, 2024

Zhuding International Limited Signs Reverse Merger Agreement with Automated Water Solutions Inc. and Belisarian Holdings

HERTS, United Kingdom, Nov. 16, 2024 (GLOBE NEWSWIRE) — Zhuding International Limited (OTC: ZHUD), a Nevada corporation, and Automated Water Solutions Inc., (AWS), a Texas corporation, are pleased to announce the signing of a Reverse Merger Agreement for the acquisition of AWS by ZHUD that will result in AWS having control over ZHUD. The effective date of the merger is 10/31/24.An application for name change has been filed and the new name of the entity will be Automated Water Solutions Inc.. A stock symbol change will be forthcoming also. The new board of directors will be W. Kyle Lewis, John H. Slocum, Dennis M Sheib, Josh Cohen, and Jon M. Andrews. Automated Water Solutions Inc. “AWS” started as a vision over five years ago of where produced water recycling efficiency needed to be. Research and observation of the technologies...

Continue reading

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patients Consistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baseline Persistently deep levels of serum TTR reductions following a single infusion remain virtually unchanged after two or more years of follow-up in over 25 patients Favorable safety and...

Continue reading

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data from FOREST-HCM Demonstrate Aficamten Durably Reduces the Proportion of Patients Guideline Eligible for Septal Reduction Therapy Analyses of Real-World Data Reveal Cost of Care Differences in HCM Across Gender, Age and Race/Ethnicity SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data relating to aficamten and hypertrophic cardiomyopathy (HCM), were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL. “These analyses add to the growing body of evidence supporting the safety and efficacy profile of aficamten and build upon primary findings related to peak VO2 and improvement in...

Continue reading

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL. “These analyses reinforce the potential treatment benefit of omecamtiv mecarbil in patients from GALACTIC-HF who are at higher risk, such as older patients or those with a recent ventricular arrhythmia,” said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. “As we prepare for the start of COMET-HF, the confirmatory Phase 3 clinical trial of omecamtiv mecarbil, we look forward to evaluating...

Continue reading

BYD emphasizes strong partner collaboration in the energy storage market during partner conference

Check out the highlights in the B-Box Journey!SHENZHEN, China, Nov. 16, 2024 (GLOBE NEWSWIRE) — BYD Co. Ltd., expands the partner program for BYD Energy Storage solutions. As part of the program, BYD held a partner conference at the BYD headquarters in November 2024, in which partners had the opportunity to voice their experiences, have an exchange with the technical team and receive an exclusive preview on upcoming new products and features.“BYD has been investing continuously into R&D as well as the production facilities to make sure energy storage solutions are not only at the forefront of the innovation curve but also produced with the highest safety standards and in a cost-efficient way,” said Yin Xiaoqiang, GM of BYD Energy Storage. “Another important factor in our product development is active...

Continue reading

BYD emphasizes strong partner collaboration in the energy storage market during partner conference

Check out the highlights in the B-Box Journey!SHENZHEN, China, Nov. 16, 2024 (GLOBE NEWSWIRE) — BYD Co. Ltd., expands the partner program for BYD Energy Storage solutions. As part of the program, BYD held a partner conference at the BYD headquarters in November 2024, in which partners had the opportunity to voice their experiences, have an exchange with the technical team and receive an exclusive preview on upcoming new products and features.“BYD has been investing continuously into R&D as well as the production facilities to make sure energy storage solutions are not only at the forefront of the innovation curve but also produced with the highest safety standards and in a cost-efficient way,” said Yin Xiaoqiang, GM of BYD Energy Storage. “Another important factor in our product development is active...

Continue reading

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved toripalimab (UK trade name: LOQTORZI®) for the treatment of two indications:Toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC); Toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with...

Continue reading

DMG Blockchain Solutions Inc. Announces Filing of Prospectus Supplement in Respect of $15,004,300 Unit Offering

The Prospectus Supplement and Base Shelf Prospectus are accessible through SEDAR+ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE DISSEMINATION, DISTRIBUTION, RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Nov. 15, 2024 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSXV: DMGI) (“DMG” or the “Company”) is pleased to announce that it has filed its prospectus supplement dated November 14, 2024 (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated October 1, 2024 (the “Base Shelf Prospectus“) in each of the provinces of Canada, except Quebec, in respect of its previously announced overnight marketed offering (the “Offering”) of 28,310,000 units of the Company (the “Units”) at a price of $0.53 per Unit for aggregate...

Continue reading

VERSES Closes Second Tranche of LIFE Offering Bringing Aggregate Funds Raised to $5.2M From Recent Offerings

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 15, 2024 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”) is pleased to announce that it closed the second tranche of its previously announced non-brokered private placement (the “LIFE Offering“) of units of the Company (the “LIFE Units“) for aggregate gross proceeds in this second tranche of $512,800. The first tranche of the LIFE Offering closed on November 8, 2024 for aggregate gross proceeds of $2,903,850. On November 8, 2024 the Company also closed a non-brokered private placement of special warrants of the Company for aggregate gross proceeds of $1,800,000. Pursuant to the second tranche of the LIFE Offering, the Company...

Continue reading

HPH Files Annual Report on Form 20-F on November 15, 2024

GUANGZHOU, China, Nov. 15, 2024 (GLOBE NEWSWIRE) — Highest Performances Holdings Inc. (NASDAQ: HPH) (“HPH” or the “Company”), today announced that it has filed its annual report for the fiscal year ended June 30, 2024 on Form 20-F (the “FY2024 20-F”), which contains its audited financial statements for the fiscal year ended June 30, 2024, with the U.S. Securities and Exchange Commission (the “SEC”) on November 15, 2024. The FY2024 20-F can be accessed on the SEC’s website at http://www.sec.gov as well as on the Investor Relations page of the Company’s website at https://ir.puyiwm.com/financial-information/sec-filings. Hard copies of the annual report are available, free of charge, to its shareholders upon request. About HPHFounded in 2010 and formerly known as Puyi Inc., we have evolved with a vision to become a leading provider...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.